Sepsis risk calculator-guided antibiotic management in neonates with suspected early-onset sepsis.
- Author:
Shi-Qi SHAO
1
;
Xin-Yin ZHANG
1
;
Kun FENG
1
;
Yun-Yan HE
1
;
Xiao-Mi XIONG
1
;
Zi-Yu HUA
1
Author Information
1. Department of Neonatology, Children's Hospital of Chongqing Medical University/Ministry of Education Key Laboratory of Child Development and Disorders/National Clinical Research Center for Child Health and Disorders/China International Science and Technology Cooperation Base of Child Development and Critical Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China.
- Publication Type:Journal Article
- MeSH:
Anti-Bacterial Agents/therapeutic use*;
Child;
Humans;
Infant;
Infant, Newborn;
Neonatal Sepsis/drug therapy*;
Retrospective Studies;
Risk Assessment;
Sepsis/drug therapy*
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(6):582-587
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the efficacy of sepsis risk calculator (SRC) in guiding antibiotic use in neonates with suspected early-onset sepsis (EOS).
METHODS:A total of 284 neonates with a gestational age of ≥ 35 weeks were enrolled as the control group, who were hospitalized in the Children's Hospital of Chongqing Medical University from March to July, 2019 and were suspected of EOS. Their clinical data were retrospectively collected and the use of antibiotics was analyzed based on SRC. A total of 170 neonates with a gestational age of ≥ 35 weeks were enrolled as the study group, who were admitted to the hospital from July to November, 2020 and were suspected of EOS. SRC was used prospectively for risk scoring to assist the decision making of clinical antibiotic management. The two groups were compared in terms of the rate of use of antibiotics, blood culture test rate, clinical outcome, and adherence to the use of SRC.
RESULTS:Compared with the control group, the study group had a significantly higher SRC score at birth and on admission (
CONCLUSIONS:The use of SRC reduces the rate of empirical use of antibiotics in neonates with suspected EOS and does not increase the risk of adverse outcomes, and therefore, it holds promise for clinical application.
